+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Visceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with adalimumab



Visceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with adalimumab



Joint, Bone, Spine 77(3): 271-273



Visceral leishmaniasis is a protozoan infection usually asymptomatic, but can progress to fatal disease in immunocompromised hosts, especially in HIV patients. Visceral leishmaniasis is rare among patients under immunosuppressive therapies, and even more among patients under anti-TNF-alpha treatment, where only four cases have been described. 1) To describe a patient with rheumatoid arthritis receiving adalimumab who developed fever, pancytopenia, splenomegaly, and extreme hyperferritinemia. 2) To perform a review of the published cases of visceral leishmaniasis and anti-TNF-alpha therapy, and cases of coexisting leishmaniasis and macrophagic activation syndrome by search in PubMed (period 1991-2008). Visceral leishmaniasis was established by bone marrow aspiration, and although there was no histological confirmation, according to HLH-2004 criteria, a secondary macrophagic activation syndrome was established. The patient had a favourable outcome. We report herein the fifth case of visceral leishmaniasis in a patient under TNF-alpha therapy, and the first one, to our knowledge, presenting a consequent secondary macrophagic activation syndrome.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056877827

Download citation: RISBibTeXText

PMID: 20378385

DOI: 10.1016/j.jbspin.2010.01.011


Related references

Visceral leishmaniasis in a patient taking adalimumab for rheumatoid arthritis. Medical Journal of Australia 198(6): 331-333, 2013

Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab. Rheumatology 45(11): 1446-1448, 2006

Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab: a case description and literature review. Enfermedades Infecciosas Y Microbiologia Clinica 28(4): 261-262, 2010

Visceral Leishmaniasis in a patient with rheumatoid arthritis undergoing treatment with methotrexate: Case report and review of the literature. European Journal of Rheumatology 4(2): 139-141, 2017

Pseudolymphomatoid cutaneous leishmaniasis in a patient treated with adalimumab for rheumatoid arthritis. Acta Dermato-Venereologica 89(4): 432-433, 2009

Visceral leishmaniasis in a patient with rheumatoid arthritis treated with methotrexate. Reumatologia Clinica 2017, 2017

Visceral leishmaniasis in a rheumatoid arthritis patient treated with methotrexate. Journal of Clinical Rheumatology 18(1): 59, 2012

Visceral leishmaniasis in a rheumatoid arthritis patient receiving methotrexate. Reumatologia Clinica 13(6): 354-356, 2016

Visceral leishmaniasis in a rheumatoid arthritis patient treated with methotrexate. International Journal of Infectious Diseases 13(4): E169-E172, 2008

Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept. Clinical Rheumatology 26(8): 1344-1345, 2006

Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with infliximab. Clinical and Experimental Rheumatology 23(6): 891-892, 2006

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). Journal of Rheumatology 30(12): 2563-2571, 2004

Pyoderma gangrenosum in a patient with seronegative rheumatoid arthritis during therapy with adalimumab: toxic effects of adalimumab or failure of adalimumab to prevent the onset of this phenomenon?. Archives of Dermatology 144(6): 817-818, 2008

An atypical presentation of visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with infliximab. Journal of Clinical Rheumatology 16(1): 38-39, 2010

Miller-Fisher syndrome in a patient with rheumatoid arthritis treated with adalimumab. Clinical Rheumatology 28(1): 93-94, 2008